Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry)

James A. Reiffel, Peter R. Kowey, Robert J Myerburg, Gerald V. Naccarelli, Douglas L. Packer, Craig M. Pratt, Michael J. Reiter, Albert L. Waldo

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry was designed to examine atrial fibrillation (AF) treatment by United States cardiologists in the context of the American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines after recent landmark clinical trials. Most patients in AFFECTS had AF without clinically significant structural heart disease or only uncomplicated hypertension. Among the all-enrolled population (n = 1,461), initial treatment strategies assigned were rhythm control in 64% and rate control in 36%. Among patients with either paroxysmal (n = 1,165) or persistent (n = 273) AF, 67% and 55%, respectively, were assigned rhythm control. The trend to assign rhythm control as the initial treatment goal decreased with age. In the rhythm-control group, most patients (74%) also received a rate-control agent during the registry, while 25% of those assigned to rate control received antiarrhythmic drugs. Most first prescriptions of antiarrhythmic drugs were for first-line therapy compliant with 2001 (76%) and 2006 (86%) guidelines. Most second prescriptions were for first-line therapies as well. Rates of serious adverse events were low. In conclusion, data from this study provide insight into community treatment patterns in patients with AF, most without clinically significant structural heart disease or with only uncomplicated hypertension.

Original languageEnglish
Pages (from-to)1122-1129
Number of pages8
JournalAmerican Journal of Cardiology
Volume105
Issue number8
DOIs
StatePublished - Apr 15 2010

Fingerprint

Atrial Fibrillation
Registries
Anti-Arrhythmia Agents
Therapeutics
Heart Diseases
Guidelines
Hypertension
Prescription Drugs
Cardiologists
Prescriptions
Clinical Trials
Control Groups
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry). / Reiffel, James A.; Kowey, Peter R.; Myerburg, Robert J; Naccarelli, Gerald V.; Packer, Douglas L.; Pratt, Craig M.; Reiter, Michael J.; Waldo, Albert L.

In: American Journal of Cardiology, Vol. 105, No. 8, 15.04.2010, p. 1122-1129.

Research output: Contribution to journalArticle

Reiffel, James A. ; Kowey, Peter R. ; Myerburg, Robert J ; Naccarelli, Gerald V. ; Packer, Douglas L. ; Pratt, Craig M. ; Reiter, Michael J. ; Waldo, Albert L. / Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry). In: American Journal of Cardiology. 2010 ; Vol. 105, No. 8. pp. 1122-1129.
@article{91a7a136ff164ddfb33f3b906c53653b,
title = "Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry)",
abstract = "The Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry was designed to examine atrial fibrillation (AF) treatment by United States cardiologists in the context of the American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines after recent landmark clinical trials. Most patients in AFFECTS had AF without clinically significant structural heart disease or only uncomplicated hypertension. Among the all-enrolled population (n = 1,461), initial treatment strategies assigned were rhythm control in 64{\%} and rate control in 36{\%}. Among patients with either paroxysmal (n = 1,165) or persistent (n = 273) AF, 67{\%} and 55{\%}, respectively, were assigned rhythm control. The trend to assign rhythm control as the initial treatment goal decreased with age. In the rhythm-control group, most patients (74{\%}) also received a rate-control agent during the registry, while 25{\%} of those assigned to rate control received antiarrhythmic drugs. Most first prescriptions of antiarrhythmic drugs were for first-line therapy compliant with 2001 (76{\%}) and 2006 (86{\%}) guidelines. Most second prescriptions were for first-line therapies as well. Rates of serious adverse events were low. In conclusion, data from this study provide insight into community treatment patterns in patients with AF, most without clinically significant structural heart disease or with only uncomplicated hypertension.",
author = "Reiffel, {James A.} and Kowey, {Peter R.} and Myerburg, {Robert J} and Naccarelli, {Gerald V.} and Packer, {Douglas L.} and Pratt, {Craig M.} and Reiter, {Michael J.} and Waldo, {Albert L.}",
year = "2010",
month = "4",
day = "15",
doi = "10.1016/j.amjcard.2009.11.046",
language = "English",
volume = "105",
pages = "1122--1129",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry)

AU - Reiffel, James A.

AU - Kowey, Peter R.

AU - Myerburg, Robert J

AU - Naccarelli, Gerald V.

AU - Packer, Douglas L.

AU - Pratt, Craig M.

AU - Reiter, Michael J.

AU - Waldo, Albert L.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - The Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry was designed to examine atrial fibrillation (AF) treatment by United States cardiologists in the context of the American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines after recent landmark clinical trials. Most patients in AFFECTS had AF without clinically significant structural heart disease or only uncomplicated hypertension. Among the all-enrolled population (n = 1,461), initial treatment strategies assigned were rhythm control in 64% and rate control in 36%. Among patients with either paroxysmal (n = 1,165) or persistent (n = 273) AF, 67% and 55%, respectively, were assigned rhythm control. The trend to assign rhythm control as the initial treatment goal decreased with age. In the rhythm-control group, most patients (74%) also received a rate-control agent during the registry, while 25% of those assigned to rate control received antiarrhythmic drugs. Most first prescriptions of antiarrhythmic drugs were for first-line therapy compliant with 2001 (76%) and 2006 (86%) guidelines. Most second prescriptions were for first-line therapies as well. Rates of serious adverse events were low. In conclusion, data from this study provide insight into community treatment patterns in patients with AF, most without clinically significant structural heart disease or with only uncomplicated hypertension.

AB - The Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry was designed to examine atrial fibrillation (AF) treatment by United States cardiologists in the context of the American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines after recent landmark clinical trials. Most patients in AFFECTS had AF without clinically significant structural heart disease or only uncomplicated hypertension. Among the all-enrolled population (n = 1,461), initial treatment strategies assigned were rhythm control in 64% and rate control in 36%. Among patients with either paroxysmal (n = 1,165) or persistent (n = 273) AF, 67% and 55%, respectively, were assigned rhythm control. The trend to assign rhythm control as the initial treatment goal decreased with age. In the rhythm-control group, most patients (74%) also received a rate-control agent during the registry, while 25% of those assigned to rate control received antiarrhythmic drugs. Most first prescriptions of antiarrhythmic drugs were for first-line therapy compliant with 2001 (76%) and 2006 (86%) guidelines. Most second prescriptions were for first-line therapies as well. Rates of serious adverse events were low. In conclusion, data from this study provide insight into community treatment patterns in patients with AF, most without clinically significant structural heart disease or with only uncomplicated hypertension.

UR - http://www.scopus.com/inward/record.url?scp=77950460086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950460086&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.11.046

DO - 10.1016/j.amjcard.2009.11.046

M3 - Article

VL - 105

SP - 1122

EP - 1129

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -